NGS panels, library preparation kits and software for cytogenetics, solid tumour and blood cancer research
Why next-generation sequencing today?
During the last 20 years, next-generation sequencing (NGS) – a method of simultaneously sequencing millions of fragments of DNA – has seen rapid adoption in the clinical research laboratory because of its ability to analyse at the same time several genes or gene regions within a single test compared to traditional methods. [1]
While the identification of single-nucleotide variants and small deletions and insertions in panel sequencing data can be considered a solved problem, the identification of larger rearrangements like multi-exon copy number variants (CNVs) still poses a considerable challenge. Germline CNVs are known to be a source of genetic diversity in humans but also the cause of various hereditary diseases, influencing a variety of Mendelian and somatic genetic disorders. Common methods used to detect CNVs are usually multiplex ligation-dependent probe amplification (MLPA), array comparative genomic hybridization (aCGH) and qPCR. However, these methods have many drawbacks, being complex, costly and requiring prior knowledge of the region to analyse. [2]
The development and widespread use of high-throughput technologies such as NGS founded the era of big data in biology and medicine. The amount of data to be processed can be overwhelming for researchers without bioinformatics know-how. In this scenario, the development of reliable, reproducible and user-friendly software tools is essential to deriving information on molecular characteristics from the NGS data. [3]
What is the SureSeq offer?
SureSeqTM NGS panels have been designed in collaboration with recognised cancer experts to detect key aberrations implicated in a wide range of haematological and solid tumour cancers. The SureSeq myPanel offers the flexibility to easily customise the catalogue available panels to fit your research requirements with the added benefit of expert-curated, regularly updated cancer content. Simply mix and match the gene, exonic or intronic content you need to create an NGS cancer panel that meets your exact requirements.
SureSeq unique panel design coupled with hybridisation-based enrichment offers unparalleled coverage completeness and uniformity, allowing accurate detection of low-frequency SNVs and indels as well as structural aberrations such as ITDs, PTDs, CNVs, LOH and translocations. Combined with our various SureSeq library preparation kit products, SureSeq alleviates the burden of running multiple assays and streamlines your research, delivering comprehensive results using a single NGS workflow.
All SureSeq panels come with Interpret, a powerful and easy-to-use NGS analysis solution that provides effortless translation of all your NGS data into meaningful results.
SureSeq panels in combination with Interpret NGS analysis software are able to detect a wide range of variants and structural aberrations.
Word cloud https://www.wordclouds.com/
SNVs and indels | Capable of detecting low-frequency SNVs and indels down to 1% VAF, including difficult to sequence regions (eg CEBPA) |
ITDs | Detect FLT3-ITDs ranging from a handful of base pairs up to >200 bp |
PTDs | Detect KMT2A-PTDs of all sizes |
CNVs and LOH | Detect CNVs ranging from loss of single exons to full chromosome arms and trisomies |
Translocations | Detect eg BCR-ABL translocations |
How can SureSeq help you overcome daily challenges?
- Panels are relevant and up to date so that you can be sure all content is informative
- SureSeq hybridisation-based panels deliver unparalleled coverage uniformity so that difficult to sequence, low-frequency variants can be consistently and confidently detected – detect low frequency SNVs, indels, ITDs, PTDs, CNV, LOH, and translocations with confidence
- One day from sample to sequencer (on specific panels) made possible by streamlined library preparation workflow
- Comprehensive or targeted? Hotspots or exons? Customise your ideal NGS cancer panel and sequence only what’s relevant for your research. Check the SureSeq myPanel pre-optimised content so that assay development time and in-house optimisation are kept to a minimum. Design your SureSeq myPanel.
- Industry-leading powerful and easy-to-use package: Interpret Software, our complimentary NGS data analysis software, accurately detects all variants and aberrations covered by your panel so that your NGS data effortlessly translates into meaningful results.
- Continuous expert consultation so that you can trust to achieve the best outcome of your NGS, every time
- Library preparation kits reagents so that your workflow is efficient and smooth
Our solutions
Discover more
More details from the manufacturer
Disclaimer
SureSeqTM: for research use only, not for use in diagnostic procedures. Product availability may vary from country to country and is subject to varying regulatory requirements. Contact your local representatives for availability.
Manufacturer and Trademarks: SureSeqTM (Oxford Gene Technology IP Limited)
References
- Yohe, S., & Thyagarajan, B. (2017). Review of Clinical Next-Generation Sequencing. Archives of pathology & laboratory medicine, 141(11), 1544–1557. https://doi.org/10.5858/arpa.2016-0501-RA
- Sorrentino, E., Daja, M., Cristofoli, F., Paolacci, S., Bertelli, M., & Marceddu, G. (2021). CNV analysis in a diagnostic setting using target panel. European review for medical and pharmacological sciences, 25(1 Suppl), 7–13. https://doi.org/10.26355/eurrev_202112_27328
